Cardiovascular pharmacogenomics is a cutting-edge field that explores the intersection of genetics and cardiovascular medicine. It focuses on how an individual's genetic makeup influences their response to cardiovascular drugs, aiming to optimize treatment outcomes and minimize adverse effects. By studying the genetic variations that affect drug metabolism, efficacy, and toxicity, researchers in cardiovascular pharmacogenomics seek to tailor medication regimens to each patient's unique genetic profile. This personalized approach holds the potential to enhance the effectiveness of cardiovascular therapies, reduce the likelihood of side effects, and improve overall patient outcomes. As our understanding of the human genome continues to advance, cardiovascular pharmacogenomics promises to play a crucial role in the evolution of precision medicine, bringing us closer to more individualized and targeted treatments for cardiovascular diseases.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India